easy-to-use teaching tool that would better predict electrolyte requirements and corresponding serum levels.
The Nutrition Subcommittee developed the algorithms on the basis of literature and clinical experience, and conditional approval by the P & T Committee was granted in 1992, The algorithms were used throughout the hospital on all types of patients, including patients with renal dysfunction and multiorgan system failure. One hundred and forty-four patients were evaluated, representing 696 patient days of PN therapy. Three hundred and seventy-six (54%) patient days were managed exclusively by our standard electrolyte composition. The remaining 320 (46%) patient days required adjustment of electrolytes. The most common reasons for adjusting electrolytes were hypokalemia, hypomagnesemia, and hypophosphatemia in trauma and refeeding, and hyperkalemia and hyperphosphatemia in renal dysfunction. There were 44 (38%) instances where the electrolyte algorithms were used and 72 (62%) incidents where traditional empiric dosing was used. In all 44 situations using the algorithms, serum electrolyte levels returned to normal within 48 hours. There were no adjustments resulting in overcorrection. The average time to correction of electrolyte abnormalities was 1.07 2 0.47 days. Of the 72 situations treated outside of the algorithms, 56 (77.8%) corrected in 1 to 6 days and 7 (9.7%) overcorrected. It took a n average of 2.5 2 1.4 days to correct the serum abnormalities (see Table 1 ). The algorithms were felt to be a significant improvement from previous therapy; therefore, the Nutrition Subcommittee recommended the adoption of the algo- mandatory, but all recommendations from the Nutritional Support Services follow the guidelines. The algorithm for acute replacement of phosphate started out as a resident project. Before the study, the standard phosphate dose for hypophosphatemia was either 15 mmoVL or 30 mmoVL. In most cases with serum levels <1.5 mg/dL, this was not enough to raise the serum phosphate level to a n acceptable level. The goal was to give a supplemental dose of phosphate that would increase serum levels to at least 2 mg/dL without causing hyperphosphatemia (serum level >4.5 mg/dL). Initial concerns included metastatic calcifications and overcorrection of serum phosphate levels. Three adjustments were made in a n attempt to alleviate these problems. The infusion rate was limited to 7.5 mmol/Wh to give the phosphate time to enter the cell and to avoid depression of serum calcium levels and metastatic calcifications; the dose was empirically decreased by 50% in patients with renal disease; and a n adjusted body weight was used in obese patients. Initial guidelines recommended were as follows: 0.125 mmol/Wkg for serum level from 1.6 to 2 mg/dL; 0.25 mmoVL/kg for levels from 1 to 1.5 mg/dL; and 0.5 mmol/l/kg for serum levels <1 mg/dL. After a pilot study, these guidelines were found subtherapeutic. The guidelines were then readjusted to their current levels (see Appendix K). Of particular interest was the fact that doses did not have to be adjusted for patients with renal dysfunction. The protocol is for acute replacement, and renal failure is not a n issue unless there is a maintenance infusion, which may allow phosphate to accumulate. Hundreds of patients have been treated using the phosphate protocol. The supplementation guidelines increase the serum phosphate to greater than 2 mg/dL in 85% to 90% of the patients treated. There was only 1 patient with resultant phosphate levels higher than 4.5 mg/dL. This patient had renal disease and was receiving maintenance phosphate. The level was taken 72 hours after the supplemental dose was given. The resultant level of 5.1 mg/dL was probably due to the maintenance fluid and not the supplemental phosphate.
Unfortunately, a controlled study comparing these algorithms with other therapy has not been done. However, since implementation of the algorithms, a reduction in the number of changes needed in PN orders and the number of electrolyte abnormalities commonly seen with PN therapy have been observed.
1.

2.
3.
4.
5.
Acute electrolyte problems are best corrected with a supplemental infusion; do not correct them with a maintenance solution such as PN. Reserve maintenance solution adjustments for chronic electrolyte problems. Be conservative, as you can always add more. If too much potassium is added to a 24-hour bag, nutritional intake may be compromised if the solution has to be discontinued. If the patient is developing renal failure, be more conservative about the amounts of potassium, phosphate, and magnesium you administer. These are only guidelines. When the clinical situation dictates, you must break from the guidelines and treat the patient as an individual. The guidelines for adjusting electrolytes were designed for PN therapy and may or may not be applicable for other maintenance solutions. Appendices G P reflect electrolyte dosing that is based on a per-kilogram amount rather than a per-liter amount. This may be more applicable for practitioners using 3:l solutions.
All of the electrolyte guidelines are similar in the manner they work. If there is a replacement dose for acute and maintenance electrolytes, both guidelines are included. 1 . Choose the electrolyte to be adjusted (ie, sodium; Appendix F). 2. Select the column with the corresponding serum electrolyte (serum sodium 133). If the patient has a dilutional hyponatremia, 35mEqL sodium would be added; if not dilutional then 7OmEqL would be added. 3. Add the amount of sodium indicated. 4. The next day, recheck the level; determine if the new level is high, low, or normal; and follow the corresponding arrow. If the serum sodium is still low (132), the sodium would be increased to 100 mEqL for nondilutional hyponatremia or to 50 mEq/L for dilutional hyponatremia. 5. Continue to follow the flow chart until the level is normal-this is the maintenance amount needed-or until 154 mEqL is reached (normal saline) or until all sodium has been removed.
Over the past several years a t my institution, we have noticed a decrease in electrolyte abnormalities seen in TPN patients. Changes in electrolytes are usually moderate, and we do not see the swings from high to low serum levels when patients are overcorrected. We feel these changes are secondary to the guidelines and a structured approach to electrolyte management. On occasion, we do have patients that cannot be managed by the guidelines, but in general they work well. 
Directions:
Begin in the column with the corresponding serum level and follow the chart accordingly. On the second day continue in the same column and make changes according to serum levels, high, low or normal. Once the patient has normal levels continue that supplementation. H = >2.4, N = 1.9-2.4, L = < 
Appendix E Potassium i~~a i n t e n a t i c c ' -~~~-'~
Cautions: Acid-base disorders, renal failure, trauma Compatibility and stability must be checked prior to mixing any parenteral nutrition solution. 
